Literature DB >> 35060391

Copper-induced tumor cell death mechanisms and antitumor theragnostic applications of copper complexes.

Yicheng Jiang1, Zhiyi Huo1, Xiaole Qi1,2, Tongmei Zuo2, Zhenghong Wu1.   

Abstract

Recent studies found that unbalanced copper homeostasis affect tumor growth, causing irreversible damage. Copper can induce multiple forms of cell death, including apoptosis and autophagy, through various mechanisms, including reactive oxygen species accumulation, proteasome inhibition, and antiangiogenesis. Hence, copper in vivo has attracted tremendous attention and is in the research spotlight in the field of tumor treatment. This review first highlights three typical forms of copper's antitumor mechanisms. Then, the development of diverse biomaterials and nanotechnology allowing copper to be fabricated into diverse structures to realize its theragnostic action is discussed. Novel copper complexes and their clinical applications are subsequently described.

Entities:  

Keywords:  Fenton reaction; antitumor; bioimaging; chemodynamic therapy; copper; phototherapy; reactive oxygen species

Mesh:

Substances:

Year:  2022        PMID: 35060391     DOI: 10.2217/nnm-2021-0374

Source DB:  PubMed          Journal:  Nanomedicine (Lond)        ISSN: 1743-5889            Impact factor:   5.307


  17 in total

1.  Cuproptosis-related gene SLC31A1 is a potential predictor for diagnosis, prognosis and therapeutic response of breast cancer.

Authors:  Xiao Li; Zhaosheng Ma; Linhang Mei
Journal:  Am J Cancer Res       Date:  2022-08-15       Impact factor: 5.942

2.  Cuproptosis predicts the risk and clinical outcomes of lung adenocarcinoma.

Authors:  Qin Hu; Runtian Wang; Huiyun Ma; Zhouwei Zhang; Qun Xue
Journal:  Front Oncol       Date:  2022-08-08       Impact factor: 5.738

3.  Identification of a Novel Cuproptosis-Related Gene Signature for Prognostic Implication in Head and Neck Squamous Carcinomas.

Authors:  Shouyi Tang; Li Zhao; Xing-Bo Wu; Zhen Wang; Lu-Yao Cai; Dan Pan; Ying Li; Yu Zhou; Yingqiang Shen
Journal:  Cancers (Basel)       Date:  2022-08-18       Impact factor: 6.575

4.  Cuprotosis-Related Genes: Predicting Prognosis and Immunotherapy Sensitivity in Pancreatic Cancer Patients.

Authors:  Yingkun Xu; Han Li; Ailin Lan; Qiulin Wu; Zhenrong Tang; Dan Shu; Zhaofu Tan; Xin Liu; Yang Liu; Shengchun Liu
Journal:  J Oncol       Date:  2022-09-09       Impact factor: 4.501

5.  A novel cuproptosis-related prognostic lncRNA signature and lncRNA MIR31HG/miR-193a-3p/TNFRSF21 regulatory axis in lung adenocarcinoma.

Authors:  Xiaocong Mo; Di Hu; Pingshan Yang; Yin Li; Shoaib Bashir; Aitao Nai; Feng Ma; Guoxia Jia; Meng Xu
Journal:  Front Oncol       Date:  2022-07-22       Impact factor: 5.738

6.  Pan-cancer analyses confirmed the cuproptosis-related gene FDX1 as an immunotherapy predictor and prognostic biomarker.

Authors:  Chi Zhang; Yuanxiao Zeng; Xiuchen Guo; Hangjing Shen; Jianhao Zhang; Kaikai Wang; Mengmeng Ji; Shengwei Huang
Journal:  Front Genet       Date:  2022-08-05       Impact factor: 4.772

7.  Cuproptosis-related lncRNA predict prognosis and immune response of lung adenocarcinoma.

Authors:  Fangwei Wang; Hongsheng Lin; Qisheng Su; Chaoqian Li
Journal:  World J Surg Oncol       Date:  2022-09-01       Impact factor: 3.253

8.  A comprehensive analysis and validation of cuproptosis-associated genes across cancers: Overall survival, the tumor microenvironment, stemness scores, and drug sensitivity.

Authors:  Jinsong Liu; Yueyao Lu; Yuyang Dai; Ying Shen; Cheng Zeng; Xiuling Liu; Huayi Yu; Jianzhong Deng; Wenbin Lu
Journal:  Front Genet       Date:  2022-08-29       Impact factor: 4.772

9.  Prognostic analysis of cuproptosis-related gene in triple-negative breast cancer.

Authors:  Shengnan Sha; Luyi Si; Xinrui Wu; Yuanbiao Chen; Hui Xiong; Ying Xu; Wangrui Liu; Haijun Mei; Tao Wang; Mei Li
Journal:  Front Immunol       Date:  2022-08-01       Impact factor: 8.786

10.  Cuproptosis scoring system to predict the clinical outcome and immune response in bladder cancer.

Authors:  Qiang Song; Rui Zhou; Fangpeng Shu; Wen Fu
Journal:  Front Immunol       Date:  2022-08-04       Impact factor: 8.786

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.